Recce Pharmaceuticals Ltd

RECEF · OTC
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Market Cap$81,880$221,817$183,730$121,356
- Cash$10,449$1,944$4,415$4,009
+ Debt$10,768$4,741$811$199
Enterprise Value$82,200$224,613$180,126$117,546
Revenue$563$6,946$0$2,381
% Growth-91.9%-100%
Gross Profit-$1,493-$1,444-$173$2,188
% Margin-265.4%-20.8%91.9%
EBITDA-$13,296-$6,988-$12,079-$9,275
% Margin-2,363.7%-100.6%-389.5%
Net Income-$13,693-$7,735-$10,200-$7,462
% Margin-2,434.2%-111.4%-313.3%
EPS Diluted-0.056-0.034-0.05-0.042
% Growth-65.4%32.4%-20.2%
Operating Cash Flow-$13,518-$6,924-$6,491-$6,517
Capital Expenditures-$8-$18-$36-$106
Free Cash Flow-$13,527-$6,942-$6,527-$6,624
Recce Pharmaceuticals Ltd (RECEF) Financial Statements & Key Stats | AlphaPilot